BioCentury
ARTICLE | Company News

SCOTUS Chief Justice denies Teva request

November 16, 2013 2:25 AM UTC

U.S. Supreme Court Chief Justice John Roberts denied a request by Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) to stay an appeals court ruling ending exclusivity for the biotech's multiple sclerosis (MS) drug Copaxone glatiramer acetate on May 24, 2014. Teva had requested the stay while it appeals to the Supreme Court a July ruling by the U.S. Court of Appeals for the Federal Circuit that invalidated a process patent covering Copaxone. The Supreme Court has not yet decided whether it will review the decision. Teva declined to comment.

The process patent held by Teva was set to expire on Sept. 1, 2015. Teva recorded U.S. Copaxone sales of $2.4 billion for the nine months ended Sept. 30 (see BioCentury Extra, July 26). ...